Cortex’ Plan For Clinical Hold Lift Approved By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will submit additional preclinical data in September on the ADHD therapy CX717.
You may also be interested in...
Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.
Cortex To Resume CX717 Alzheimer Study, Initiate ADHD Trial
Announcement comes after FDA approves a study protocol with higher doses of the Ampakine compound.